Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 201 - 229 av 229 resultater
Tid
Selskap
Tittel
Sektor
Kategori
28 Mar 2022
18:00 CEST
MAAT PHARMA
MaaT Pharma annonce le traitement d’un premier patient dans l’étude clinique « ARES » de Phase 3 évaluant MaaT013 dans le traitement de la maladie aiguë du greffon contre l’hôte
20103010 Biotechnology
New
28 Mar 2022
18:00 CEST
MAAT PHARMA
MaaT Pharma Announces First Patient Dosed in Phase 3 ‘ARES’ Trial Evaluating MaaT013 in Patients with Acute Graft-vs-Host-Disease
20103010 Biotechnology
New
21 Mar 2022
18:00 CET
MAAT PHARMA
MaaT Pharma Announces the Implementation of a Liquidity Contract with Kepler Cheuvreux
20103010 Biotechnology
Other financial transaction
21 Mar 2022
18:00 CET
MAAT PHARMA
MaaT Pharma annonce la mise en œuvre du contrat de liquidité avec Kepler Cheuvreux
20103010 Biotechnology
Other financial transaction
17 Mar 2022
18:00 CET
MAAT PHARMA
MaaT Pharma to Present Promising Clinical Data for Lead Therapeutic Candidate MaaT013 at 48th EBMT Annual Meeting
20103010 Biotechnology
Meetings / events
17 Mar 2022
18:00 CET
MAAT PHARMA
MaaT Pharma présentera des données cliniques prometteuses pour MaaT013, son candidat-médicament le plus avancé, lors de la 48ème rencontre annuelle de l’EBMT
20103010 Biotechnology
Meetings / events
28 Feb 2022
18:00 CET
MAAT PHARMA
MaaT Pharma Reports Cash and Revenues for Full-Year 2021
20103010 Biotechnology
Other financial transaction
28 Feb 2022
18:00 CET
MAAT PHARMA
MaaT Pharma publie sa position de trésorerie et son chiffre d’affaires pour l’exercice 2021
20103010 Biotechnology
Other financial transaction
09 Feb 2022
18:00 CET
MAAT PHARMA
MaaT Pharma SA: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
20103010 Biotechnology
New
08 Feb 2022
18:00 CET
MAAT PHARMA
MaaT Pharma and Skyepharma Have Entered a Partnership to Establish the First Exclusive Microbiome Ecosystem Therapies cGMP Manufacturing Facility in France
20103010 Biotechnology
Alliances and agreements
08 Feb 2022
18:00 CET
MAAT PHARMA
MaaT Pharma et Skyepharma annoncent leur partenariat pour lancer la première usine française de production exclusivement dédiée aux biothérapies issues du microbiote
20103010 Biotechnology
Alliances and agreements
26 Jan 2022
18:00 CET
MAAT PHARMA
MaaT Pharma Announces Ordinary and Extraordinary Shareholders’ General Meeting on March 3, 2022, and the Availability of Preparatory Documents
20103010 Biotechnology
General meeting / Board Meeting
26 Jan 2022
18:00 CET
MAAT PHARMA
MaaT Pharma annonce une Assemblée Générale ordinaire et extraordinaire le 3 mars 2022 et les modalités de mise à disposition des documents préparatoires
20103010 Biotechnology
General meeting / Board Meeting
24 Jan 2022
07:30 CET
MAAT PHARMA
MaaT Pharma Announces Positive Interim Engraftment Data for Oral Formulation MaaT033 Allowing Early Termination of Phase 1b CIMON Study
20103010 Biotechnology
Other subject
24 Jan 2022
07:30 CET
MAAT PHARMA
MaaT Pharma annonce des résultats intermédiaires positifs de colonisation pour MaaT033, sa formulation orale, permettant de conclure plus rapidement l’essai CIMON de Phase 1b
20103010 Biotechnology
Other subject
17 Jan 2022
18:00 CET
MAAT PHARMA
MaaT Pharma Provides Business Objectives and Expected Milestones for 2022
20103010 Biotechnology
Other subject
17 Jan 2022
18:00 CET
MAAT PHARMA
MaaT Pharma présente ses objectifs et les prochaines étapes de développement pour l’année 2022
20103010 Biotechnology
Other subject
13 Jan 2022
19:00 CET
MAAT PHARMA
MaaT Pharma Announces Initiation of Coverage of its Stock by KBC Securities, Kempen and Portzamparc/Groupe BNP Paribas
20103010 Biotechnology
New
13 Jan 2022
19:00 CET
MAAT PHARMA
MaaT Pharma annonce l’initiation de la couverture de son titre par KBC Securities, Kempen et Portzamparc / Groupe BNP Paribas
20103010 Biotechnology
New
03 Jan 2022
19:00 CET
MAAT PHARMA
MaaT Pharma annonce sa participation à la conférence virtuelle H.C. Wainwright BioConnect 2022
20103010 Biotechnology
Other subject
03 Jan 2022
19:00 CET
MAAT PHARMA
MaaT Pharma to Present at H.C. Wainwright BioConnect 2022 Virtual Conference
20103010 Biotechnology
Other subject
03 Jan 2022
18:00 CET
MAAT PHARMA
MaaT Pharma S.A. : Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
20103010 Biotechnology
Other financial transaction
11 Dec 2021
21:00 CET
MAAT PHARMA
MaaT Pharma Presents Promising Clinical Data from 76 Patients with Acute Graft-vs-Host-Disease Treated with MaaT013 at 63rd ASH Annual Meeting
20103010 Biotechnology
Other subject
11 Dec 2021
21:00 CET
MAAT PHARMA
MaaT Pharma présente, à l’occasion de la 63ème rencontre annuelle de l’ASH, des résultats cliniques prometteurs issus de 76 patients atteints de la maladie du greffon contre l’hôte aigüe traités avec MaaT013
20103010 Biotechnology
Other subject
06 Dec 2021
07:30 CET
MAAT PHARMA
MaaT Pharma Announces the Partial Exercise of the Over-Allotment Option and the Total Size of the Offering at Approximately €35.7m
20103010 Biotechnology
Other financial transaction
06 Dec 2021
07:30 CET
MAAT PHARMA
MaaT Pharma annonce l’exercice partiel de l’option de surallocation et le montant définitif de l’offre porté à environ 35,7 M€
20103010 Biotechnology
Other financial transaction
02 Dec 2021
09:23 CET
MAAT PHARMA
MaaT Pharma Will Host Investor Information Meeting Following Presentation at ASH Conference of Additional Results on MaaT013
20103010 Biotechnology
Meetings / events
01 Dec 2021
19:30 CET
MAAT PHARMA
MaaT Pharma organisera une réunion d'information à destination des investisseurs après la présentation de résultats complémentaires de MaaT013 lors de la conférence de l'ASH
20103010 Biotechnology
Meetings / events
25 Nov 2021
20:35 CET
MAAT PHARMA
MaaT Pharma S.A. : Opérations de stabilisation
20103010 Biotechnology
Other financial transaction
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
3
4
5
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Stock options
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva